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Purpose:  Transforming  growth  factor  (TGF)-β2  induction  of  epithelial-mesenchymal  transition  of  retinal  pigment
epithelium  (RPE)  cells  has  been  implicated  to  be  an  important  event  during  the  development  of  proliferative
vitreoretinopathy. The present study was conducted to examine whether troglitazone (TGZ) can inhibit TGFβ2-mediated
fibrosis of RPE cells. The mechanism of the TGZ effect was also investigated by studying major TGFβ2-induced signaling
including activation of Smad and p38 mitogen activated protein kinase (MAPK).
Methods: Human RPE cells (ARPE-19) were exposed to various concentrations of TGZ in the presence of TGFβ2. The
inhibitory effects of TGZ on collagen type I (COLI) and fibronectin (FN) expression induced by TGFβ2 was evaluated
by reverse transcriptase-polymerase chain reaction. COLI synthesis was evaluated by the concentration of the C-terminal
propeptide of COLI in the medium. The protein levels of FN and the phosphorylation of p38 MAPK and Smad2 and
Smad3 were assessed by immunoblotting. TGZ inhibition of TGFβ2-promoted ARPE-19 cell migration was evaluated
by an in vitro wound-healing assay. The influence of TGZ on cell viability was evaluated by the colorimetric conversion
of 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide.
Results: TGZ dose-dependently inhibited TGFβ2-induced COLI and FN overexpression at the levels of mRNA and
protein manufacture. A dose-dependent TGZ inhibition was also apparent in TGFβ2-induced cell migration; cell viability
was unaffected. TGFβ2 induced sequential phosphorylation of Smad2 and Smad3 and p38 MAPK. TGZ inhibited
TGFβ2-induced early Smad2 and Smad3 and late Smad3 phosphorylation but had no influence on TGFβ2-induced p38
MAPK activation.
Conclusions: TGZ pretreatment can significantly prevent TGFβ2-induced epithelial- mesenchymal transition of RPE
cells, and retards cell migration. This may be achieved through the prevention of TGFβ2-induced Smad2 and Smad3
phosphorylation and subsequent nuclear accumulation. On the other hand, TGZ does not alter the levels of TGFβ2-induced
p38 MAPK phosphorylation, the effect of TGZ is unlikely to be mediated by p38 MAPK signaling.
Retinal pigment epithelium (RPE) cells form a monolayer
at  the  blood-retina  barrier  between  the  retina  and
choriocapillaries. Following retinal detachment, changes that
frequently  occur  in  RPE  cells  in  the  vitreous  cavity  and
subretinal  space  include  proliferation  and  production  of
extracellular matrix (ECM) components on the retina. This
disease process is called proliferative vitreoretinopathy (PVR)
[1,2]. The fibrous tissue on the detached retina ultimately
reduces the flexibility of the detached retina [3] and becomes
a  major  cause  for  failure  of  retinal  reattachment  surgery.
Agents capable of preventing migration and fibrogenesis of
RPE cells may be of great therapeutic value in improving the
success rate of retinal reattachment surgery.
Transforming growth factor (TGF)-β is a potent fibrotic
factor responsible for the synthesis of ECM. TGF-β plays a
key role in pathogenesis of chronic fibroses, including kidney,
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liver, and lung [4-6]. Analysis of vitreous humor from patients
who have experienced retinal detachments reveals levels of
TGFβ2  that  correlate  with  intraocular  fibrosis  and  PVR
severity [7]. In addition, RPE-mediated retinal contraction in
an organ culture model can be reduced by the neutralizing
antibody  against  TGFβ2;  exogenous  TGFβ2  can  further
stimulate RPE cell-mediated retinal contraction [8]. TGFβ2
may also function as an initiator to upregulate various PVR-
inducing  factors  such  as  platelet-derived  growth  factor
(PDGF) and connective tissue growth factor (CTGF) in the
pathogenesis of PVR [9,10]. In cultured RPE cells, TGFβ2
induces  the  transformation  of  RPE  to  fibroblast-like  cells
[11],  production  of  ECM  such  as  collagen  type  I  and
fibronectin [9,12,13], and cell migration [13].
Phosphorylation of Smad3 and p38 mitogen-activated
protein kinase (MAPK) are sequentially induced by TGFβ2,
and both are important for mediating TGFβ2-induced fibrosis
in ARPE-19 cells, a human RPE cell line that serves as an in
vitro model [9,12,13]. The absence of fibrous tissue in the
subretinal space in a mouse model of retinal detachment has
been demonstrated in Smad3 null mice [9]. On the other hand,
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95adenoviral  gene  transfer  of  dominant-negative  (DN)
p38MAPK to a mouse model of PVR has demonstrated the
decreased ECM production in the subretinal space, consistent
with  a  potential  therapeutic  efficacy  via  the  inhibition  of
p38MAPK [13]. These results support the essential role of
both signaling pathways in PVR. Interestingly, inhibition of
p38  MAPK  activity  suppresses  TGFβ2-induced  ECM
production of RPE cells but has no affect on TGFβ2-induced
Smads2/3  phosphorylation  [12,13].  However,  it  remains
unclear whether p38 MAPK is a downstream effector of Smad
cascade  or  is  part  of  an  independent  signaling  pathway
contributing to fibrogenesis of RPE cells.
Thiazolidinediones (TZDs) such as troglitazone (TGZ)
are a novel class of oral hypoglycemic drugs used to improve
insulin resistance in non-insulin-dependent diabetes mellitus
[14].  TZDs  serve  as  ligands  of  peroxisome  proliferator-
activated  receptor  gamma  (PPARγ),  a  ligand-dependent
transcription  factor  that  possesses  pleiotropic  effects;
examples  include  regulation  of  adipogenesis,  insulin
sensitization,  angiogenesis,  and  inflammation  [15,16].
PPARγ ligands have the potential to suppress the fibrogenesis
of  hepatic  stellate  cells  [17,18]  and  lung  fibroblasts  [19].
However, it is uncertain whether PPARγ ligands can suppress
TGFβ2-mediated ECM production of RPE cells.
PPARγ ligands are capable of reducing fibrogenesis in
several  different  types  of  cells  [6,17-20].  This  led  us  to
investigate the influence of TGZ, which is a PPARγ agonist,
on TGFβ2-mediated responses in RPE cells. Presently, we
report that TGZ can efficiently inhibit production of ECM
components  and  cell  migration  in  TGFβ2-stimulated
ARPE-19 cells. As well, TGZ can suppress TGFβ2-induced
phosphorylation  of  Smad  2  and  3,  providing  a  possible
molecular mechanism to explain the TGZ inhibitory effect.
METHODS
Cell Culture and treatment: Cells of the human RPE line
ARPE-19 were obtained from the American Type Culture
Collection  (ATCC;  Manassas,  VA).  ARPE-19  is  an
immortalized cell line that spontaneously arose from cultures
of human RPE [21]. The cells were cultured in a humidified
incubator at 37 °C in 5% CO2 in 10% fetal bovine serum-
defined  minimal  essential  medium  (FBS-DMEM)-F12
medium  supplemented  with  100  U/mL  penicillin  G  and
100  μg/mL  streptomycin.  When  cultures  achieved
confluence, the spent medium was removed and replaced with
fresh FBS-free medium. After 24 h of serum starvation, cells
were treated with recombinant human TGFβ2 (R&D Systems,
Minneapolis,  MN)  as  previously  described  [12,13].  For
inhibitor studies, cells were preincubated with SB203580 or
TGZ  (Calbiochem,  San  Diego,  CA)  for  1  h  followed  by
TGFβ2  treatment.  The  inhibitors  dissolved  in  DMSO
(DMSO) were added to the cell culture (the final concentration
of DMSO was less than 0.05%).
Cell lysis, fractionation, and electrophoresis: ARPE-19 cells
were scraped into lysis buffer (150 μL in each 35 mm well of
the microtiter plate) containing 20 mM HEPES (pH 7.4), 1%
sodium dodecyl sulfate (SDS), 150 mM NaCl, 1 mM EGTA,
5 mM β-glycerophosphate, 10 mM sodium pyrophosphate,
10  mM  sodium  fluoride,  100  μM  sodium  orthovanadate,
10 μg/mL leupeptin, and 10 μg/mL aprotinin. The lysate was
incubated on ice for 15 min. Cell debris was removed by
centrifugation (15,000 rpm, 15 min, 4 °C). For extraction of
cytoplasmic and nuclear fractions, the NE-PER™ nuclear and
cytoplasmic extraction kit (Pierce, Rockford, IL) was used
according  to  the  manufacturer’s  instructions.  Samples
containing 20 μg of protein were analyzed by 12% SDS–
PAGE  and  electrotransferred  to  polyvinylidene  fluoride
membranes  (Immobilon-P;  Millipore,  Bedford,  MA)  and
processed for western blotting.
Western blot analysis: Samples were probed with anti-Active
p38  pAb  (Promega,  Madison,  WI),  anti-phospho-Smad2
(S465/S467, Upstate Biotechnology, Lake Placid, NY), anti-
phospho-Smad3  (S423/S425,  R&D  Systems,  Minneapolis,
MN),  or  anti-phospho-HSP27  (Ser78)  antibody  (Upstate
Biotechnology) according to the manufacturer’s instructions,
and then washed three times in Tris-buffered saline containing
0.1%  Tween  20  (TBST).  Antibody  directed  against  p38/
SAPK2  (Upstate  Biotechnology),  Smad2  (Abcam  Ltd,
Cambridge,  UK),  Smad3  (Zymed  Laboratories,  San
Francisco, CA), or β-actin (Sigma-Aldrich, St. Louis, MO)
were used to verify equal loading of protein. The blots were
incubated  with  horseradish  peroxidase-labeled  anti-rabbit
secondary antibody (Amersham Biosciences, Piscataway, NJ)
diluted in TBST for 1 h and washed three times in TBST
before  visualization  using  an  enhanced  chemiluminescent
technique. X-ray films were scanned on the Model GS-700
imaging densitometer (Bio-Rad Laboratories, Hercules, CA)
and analyzed using Labworks 4.0 software (UVP, Upland,
CA). For quantification, blots of at least three independent
experiments were used.
Measurement of the C-terminal propeptide of collagen type I:
After treatment for 48 h, 20 μL of the conditioned medium
was analyzed for collagen type I C-terminal peptide by an
enzyme-linked  immunosorbant  assay,  according  to  the
manufacturer’s method (TaKaRa Biochemicals Co., Osaka,
Japan).
Semi-quantitative  reverse  transcriptase-polymerase  chain
reaction (RT–PCR): Total RNA was extracted from ARPE-19
cells  with  TRIzol™  reagent  (Invitrogen,  Carlsbad,  CA),
according to the manufacturer’s protocol. Synthesis of cDNA
was performed with 1 µg of total RNA at 50 °C for 50 min,
using  oligo  (dT)  primers  and  reverse  transcriptase
(Superscript III, Invitrogen). The amplification mixture (final
volume 20 μl) contained 1 × Taq polymerase buffer, 0.2 mM
dNTPs, 1.5 mM MgCl2, 1 μM primer pair, and 0.5 U of Taq
DNA  polymerase  (Life  Technologies,  Inc.,  Gaithersburg,
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reaction with fibronectin primers 5`-tcgaggaggaaattccaatg-3`
(forward)  and  5`-ctcttcatgacgcttgtgga  −3`  (reverse),  or
collagen  type  I  primers  5`-ggagggaatcactggtgcta  −3`
(forward) and 5`-agggggaaaaactgctttgt-3` (reverse) yielding a
300-bp  product.  The  number  of  cycles  for  the  primer  set
(denaturation for 20s at 94 °C; annealing for 30s and 59 °C;
and polymerization for 40s at 72 °C) was chosen to be in the
linear range of amplification.
Cell migration assay: Cells (1 × 106) were plated on 6-well
culture plates (Corning, Corning, NY) in serum-free DMEM-
F12. The cell layer was scratched with a pipette tip. The
culture was then incubated with various reagents. Photographs
of the wound were taken using a Nikon ECLIPSE TS100
microscope at various time points after monolayer wounding.
Cell migration was evaluated by assaying the closure of a
linear  defect  produced  in  a  cell  monolayer  culture  as
previously reported [13].
Cell  viability:  ARPE-19  cells  were  seeded  in  10%  FBS-
DMEM-F12 medium in 96-well microculture plates (12,000
cells/well, Nunclon, Roskilde, Denmark) for 24 h. The culture
medium  was  then  replaced  by  serum-free  DMEM-F12
medium for 16 h. At the time, the cell density before TGFβ2
or TGZ treatment was around 22,000 cells/well. Cells were
received  serum-free  medium  containing  various
concentrations of TGZ or were treated with 4 ng/ml TGFβ2
for  48  h.  Cell  viability  was  determined  by  the  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide
(MTT) assay, and confirmed by the trypan blue exclusion
assay [22]. For performance of trypan blue exclusion assay,
at the end of the cytotoxicity test, the cells were incubated with
0.05% trypan blue for 30 min.
Statistical analysis: Data are expressed as mean ± standard
deviation (SD) of three independent experiments, each done
in triplicate (n=3–4 dishes). The Mann–Whitney U test was
used to determine statistically significant differences. P values
< 0.05 were considered significant.
RESULTS
TGZ inhibits TGFβ2-induced fibronectin: Since fibronectin
and collagen type I are the major ECM components of PVR
tissue  [13],  we  investigated  whether  TGZ  could  prevent
TGFβ2-induced  fibronectin  protein  in  ARPE-19  cells.  As
shown  in  Figure  1A,  western  blot  analysis  revealed  that
exogenous TGFβ2 significantly increased fibronectin protein
levels after treatment for 48 h as compared to 24 h treatment.
Cells  pretreated  with  10  μM  TGZ  prevent  the  TGFβ2-
mediated induction of fibronectin; at all time periods, the
fibronectin  level  of  the  pretreated  cells  were  similar  as
TGFβ2-untreated cells. DMSO pretreatment had no effect.
p38  MAPK  activation  can  be  induced  by  TGFβ2  and  is
essential for TGFβ2-induced ECM production [12,13]. Our
results  also  revealed  that  a  similar  inhibition  effect  was
evident in cells pretreated with equal concentrations of a p38
MAPK inhibitor (SB203580) or TGZ.
Exposure of ARPE-19 cells to 1–4 ng/mL TGFβ2 for 48
h increased fibronectin protein levels in a dose-dependent
manner (Figure 1B, lanes 2–4). To examine the TGZ dose
effect  on  TGFβ2-induced  fibronectin  protein,  cells  were
pretreated for 1 h with 1–10 μM TGZ before addition of 4 ng/
ml TGFβ2 for a further 48 h. Immunoblotting results revealed
Figure  1.  TGZ  blocks  TGFβ2-induced  fibronectin  expression  in
ARPE-19 cells. A: Time-course study of the effect of TGZ on the
TGFβ2-induced fibronectin expression. ARPE-19 cells were either
left untreated (UT) or were treated with 4 ng/ml TGFβ2, or were
pretreated  with  10  μM  TGZ,  10  μM  SB203580  (p38  MAPK
inhibitor), or DMSO for 1 h and then exposed to TGFβ2 for the
indicated time periods. Immunoblot results are from a representative
experiment performed in triplicate with β-actin as loading control.
B: Dose study of the effect of TGZ on TGFβ2-induced fibronectin
expression.  ARPE-19  cells  were  treated  with  different  doses  of
TGFβ2 (1, 2, 4 ng/ml; lanes 2–4) for 48 h or pretreated with different
doses of TGZ (1, 5, 10 μM; lanes 5–7) for 1 h before 4 ng/ml
TGFβ2 treatment for additional 48 h. Immunoblot results are from a
representative experiment performed in triplicate with β-actin as
loading control. C: After densitometric scans of triplicate blots,
values for fibronectin were normalized to β-actin. *p<0.05 versus 4
ng/ml TGFβ2-treated cells.
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induction  of  fibronectin  protein  (approximately  0.5-fold
induction,  similar  to  the  induction  produced  by  2  ng/ml
TGFβ2) (Figures 1B and 1C).
TGZ inhibits TGFβ2-induced collagen type I: To examine
whether TGZ could prevent TGFβ2-induced collagen type I
protein,  we  measured  the  concentration  of  the  C-terminal
propeptide of collagen type I (PICP) in the medium. As shown
in  Figure  2,  exogenous  TGFβ2  increased  collagen  type  I
protein levels, consistent with previous reports [12,13]. Cells
pretreated for 1 h with 1–10 μM TGZ before the 48 h addition
of 4 ng/ml TGFβ2 suppressed TGFβ2-induced collagen type
I in a dose-dependent fusion. Pretreatment with DMSO had
no such effect. In addition, 5 μM TGZ had an inhibitory effect
exceeded that obtained following pretreatment with 10 μM
SB203580.
TGZ inhibits TGFβ2-induced collagen type I and fibronectin
mRNA expression: Next, we investigated whether TGZ was
capable of inhibition of TGFβ2-induced collagen type I and
fibronectin mRNA expression. As shown in Figure 3, RT–
PCR analysis demonstrated that ARPE-19 cells cultured in
serum-free medium expressed a basal level of collagen type I
and fibronectin genes; treatment with exogenous TGFβ2 for
24 h markedly induced expression of both mRNAs. Cells
treated  with  TGFβ2  for  8  h  also  displayed  an  increased
Figure  2.  TGZ  attenuates  TGF-β2-induced  collagen  type  I
production  in  ARPE-19  cells.  ARPE-19  cells  were  either  left
untreated or were treated with 4 ng/ml TGFβ2 for 48 h, or were
pretreated with TGZ (1, 5, 10 μM), 10 μM SB203580, or DMSO for
1 h and then exposed to TGFβ2 for additional 48 h. The concentration
of PICP (C-terminal propeptide of collagen type I) in the culture
media  under  the  various  treatment  conditions  was  measured  by
ELISA. Data represent the mean ± SD of results in four independent
experiments. *p<0.01, compared with TGFβ2-treated cells. #p<0.05,
versus SB203580-pretreated cells.
expression of both mRNAs but at levels less than following
stimulation for 24 h (approximately threefold). The TGFβ2-
mediated  induction  effect  was  completely  blocked  by
actinomycin D pretreatment, suggesting that the increased
mRNA  expression  was  transcription  dependent.  Cells
pretreated for 1 h with 10 μM TGZ before TGFβ2 treatment
suppressed TGFβ2-induced collagen type I and fibronectin
mRNA to basal levels that were comparable to untreated cells.
Pretreatment  with  DMSO  had  no  such  effect.  Similarly,
10 μM SB203580 pretreatment partially prevented TGFβ2-
induced collagen type I mRNA expression (compare Figure 2
with Figure 3).
Next,  we  investigated  whether  TGZ  could  prevent
TGFβ2-induced expression of fibronectin and collagen type I
in subconfluent ARPE-19 cells. As shown in Figure 4A, RT–
PCR  analysis  revealed  that  both  mRNAs  were  markedly
upregulated by TGFβ2 treatment for 24 h and the TGFβ2-
mediated induction effect was blocked by TGZ pretreatment
followed  a  dose-dependent  manner.  Pretreatment  of
subconfluent ARPE-19 cells with TGZ (1–10 μM, 1h) also
dose-dependently suppressed TGFβ2-induced fibronectin and
collagen type I proteins as assayed by western blot analysis
and ELISA (PICP), respectively (Figure 4B and 4C). DMSO
pretreatment had no effect. Collectively, our results revealed
that  TGZ  suppresses  TGFβ2-mediated  fibrogenesis  in
ARPE-19 cells grown to either confluence or subconfluence.
TGZ  inhibits  TGFβ2-induced  cell  migration:  TGFβ2-
mediated  promotion  of  RPE  cell  migration  has  been
implicated in the development of PVR [23]. We examined this
in more detail using an in vitro wound healing assay in which
Figure 3. TGZ decreases TGFβ2-induced expression of fibronectin
and collagen type I mRNA in ARPE-19 cells. ARPE-19 cells were
either left untreated or were treated with 4 ng/ml TGFβ2 for 24 h, or
were  pretreated  with  10  μM  TGZ,  DMSO  (0.05%),  10  ng/ml
Actinomycin D, or 10 μM SB203580 for 1 h and then incubated with
TGFβ2 for additional 24 h. Total RNA was extracted, and RT–PCR
analysis for fibronectin and collagen type I (COLI) was performed.
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) expression
was  examined  for  normalization  purposes.  Experiments  were
repeated twice and the results were reproducible.
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Figure 4. TGZ suppresses TGFβ2-induced expression of fibronectin
and collagen type I in subconfluent ARPE-19 cells. ARPE-19 cells
at subconfluent density of 5 X 105 cells per well in six-well plates
were either left untreated (UT) or were treated with 4 ng/ml TGFβ2,
or were pretreated with different doses of TGZ (1, 5, 10 μM; 1 h) or
DMSO  (0.05%,  1  h)  and  then  incubated  with  TGFβ2.  The
expressions of fibronectin and collagen type I were assayed by RT–
PCR analysis (A), western blot analysis (B), and ELISA (C) as
Figures  1–3  described.  *p<0.05  versus  TGFβ2-treated  cells.
Experiments were repeated twice and the results were reproducible.
remaining defect. As shown in Figure 5B, addition of TGFβ2
significantly enhanced the cell migration (compared untreated
cells  with  TGFβ2-treated  cells  at  24  h  post-wounding;
p<0.01). Cells pretreated with 5 and 10 μM TGZ suppressed
TGFβ2-promoted cell migration in all the time periods studied
(approximately  50  and  72%  of  the  remaining  defect  as
compared to the original defect), but 1 μM TGZ or DMSO had
no  inhibitory  effect.  Figure  5A  shows  representative
photographs  of  cells  migrating  into  scratch  wounds.  Our
results  also  revealed  that  a  similar  inhibition  effect  was
obtained  from  cells  pretreated  with  10  μM  SB203580  or
5 μM TGZ before TGFβ2 treatment for 48 h (**p<0.05 versus
48 h TGFβ2-treated cells).
To confirm that the effect of TGZ on wound gap was not
a result of TGZ cytotoxicity on ARPE-19 cells, cells were
exposed to increasing concentrations of TGZ (1–10 μM) in
serum-free medium for 48 h, and cell viability was examined
using an MTT assay. As shown in Figure 6A, TGZ did not
affect cell viability even in cells treated with 10 μM TGZ,
although  proliferation  of  ARPE-19  cells  was  evident;  the
latter is consistent with another study [13]. However, 10 μM
TGZ showed no further inhibitory effect on cell proliferation
in the presence of TGFβ2. To further confirm that TGZ at
10 μM does not affect RPE survival at the region of wound
healing,  cell  viability  was  evaluated  using  trypan  blue
exclusion assay. Results revealed that 10 μM TGZ did not
affect  cell  survival  while  50  μM  TGZ  treatment  caused
massive cell death and trypan blue staining (Figure 6B).
The TGZ inhibition effect is independent to the activation of
PPARγ:  To  investigate  whether  TGZ  acts  through  the
activation of its receptor PPARγ to suppress TGFβ2-mediated
reactions, ARPE-19 cells were pretreatment for 2 h with 5–
20  μM  GW9662,  a  specific  PPARγ  antagonist,  and  then
assayed  for  PPARγ  levels,  fibronectin  levels  and  cell
migration in the presence of 10 μM TGZ combining with
TGFβ2. As showed in Figure 7A, western blots showed that
there  was  no  change  in  the  PPARγ  protein  levels  with
exposure  to  TGZ  in  the  presence  of  TGFβ2.  In  addition,
GW9662 did not reverse the inhibition of TGFβ2-induced
fibronectin production (Figure 7A). in vitro wound healing
assay also revealed that TGZ suppressed TGFβ2-promoted
cell migration can not be reversed by GW9662 (Figure 7B,
compared TGFβ2+TGZ with GW9662+TGFβ2+TGZ-treated
cells at 48 h post-wounding). Therefore, the results led us to
suggest  that  TGZ-mediated  inhibitions  are  through  a
PPARγ-independent mechanism.
TGZ  does  not  affect  the  TGFβ2-induced  p38  MAPK
phosphorylation:  We  further  investigated  whether  TGZ
affected TGFβ2-induced p38 MAPK signaling to suppress
TGFβ2-mediated  responses  in  ARPE-19  cells.  Cells  were
treated with TGFβ2 or pretreated for 1 h with 10 μM TGZ
before  TGFβ2  treatment  for  various  time  periods.
Subsequently, the phosphorylation status of the p38 MAPK
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8B,  TGFβ2  stimulation  caused  phosphorylation  of  p38
MAPK, which was transiently upregulated at 6 h as previously
reported [13]. However, TGFβ2 still caused a similar p38
MAPK phosphorylation in TGZ-pretreated cells in all the time
periods  studied,  suggesting  TGZ  can  non  inhibit  the  p38
MAPK phosphorylation. In addition, DMSO had no effect on
basal and TGFβ2-induced p38 MAPK phosphorylation (data
not shown).
Figure  5.  TGZ  reduces  TGFβ2-promoted  healing  of  wounds  in
ARPE-19  cell  monlayers.  Cell  monolayers  were  pretreated  with
vehicle (DMSO), TGZ (1, 5, 10 μM), or 10 μM SB203580 for 1 h
and then treated with 4 ng/ml TGFβ2 and wounded with a P-200
pipette tip immediately after 0 h. Wells were photographed at 0, 24,
and 48 h adjacent to a reference line scraped on the bottom of the
plate.  A:  Panels  show  migration  of  cells  pretreated  with  either
DMSO, 10 μM TGZ, or 10 μM SB202190 before treatment with
TGF-β2 for 0, 24, and 48 h as indicated. B: Percent of remaining
wound width in monolayer cell sheet. The data show the percent
remaining wound closure in each culture condition. For this value,
the width was measured at three different locations in the wound and
the mean value was compared to the width of the original closure (0
h). All experiments were in triplicate. Bars represent the mean ± SD
#p<0.01  versus  24  h  untreated  cells  and  *p<0.05  versus  24  h
TGFβ2-treated cells. **p<0.05 versus 48 h TGFβ2-treated cells.
To further ensure that TGZ dose not affects p38 MAPK
signaling,  we  examined  the  levels  of  phosphorylation  of
HSP27, a documented substrate of p38 MAPK signaling in
ARPE-19  cells  [24].  Results  showed  that  TGZ,  at  the
concentration  that  can  attenuate  fibronectin  expression
(Figure  8C),  does  not  change  the  levels  of  HSP27
Figure 6. TGZ at 10 μM has no effect on ARPE-19 cell proliferation
either in the presence or absence of TGFβ2. ARPE-19 cells were
either left untreated or treated with 10 μM TGZ, 0.05% DMSO, or 4
ng/ml TGFβ2, or were treated with TGFβ2 combining with TGZ or
DMSO for 48 h as indicated. Cell viability was estimated by MTT
assay (A) or trypan blue exclusion assay (B). TGZ at 50 μM is
cytotoxic and used as positive control of trypan blue exclusion assay.
Bars represent the mean ± SD *p<0.05 versus untreated cells.
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8D), whereas SB203580 dose-dependently inhibited HSP27
phosphorylation.  These  suggest  that  TGZ  inhibit  TGFβ2-
induced  fibrogenesis  through  a  p38  MAPK-independent
mechanism.
TGZ  suppresses  TGFβ2-induced  Smad  phosphorylation:
Since  Smad  signaling  has  been  implicated  in  TGFβ2-
dependent induction of ECM components [9], we examined
whether the TGZ could affect C-terminal phosphorylation of
Smad 2 and 3 by western blot analysis. As shown in Figure
9A, cell exposure to TGFβ2 induced phosphorylation of both
Smad species not only after treatment for 2 h, but also was
sustained for 24 h, as in previous studies [9,13]. SB203580
had no significant effect on the phosphorylation of Smad2 in
all  the  time  periods  studied  but  partially  prevented
phosphorylation of Smad3 after TGFβ2 stimulation for 24 h
(65  ±  12%  lower  than  TGFβ2-treated  cells;  Figure  9C).
Exposure  of  cells  to  10  μM  TGZ  partially  suppressed
TGFβ2-induced  Smad2  phosphorylation  (36  ±  8%  versus
TGFβ2 treatment for 2h) but had no effect on the levels of
Smad2  phosphorylation  stimulated  by  TGFβ2  for  24  h
(Figures 9A and 9B). Notably, TGZ suppressed the levels of
Smad3 phosphorylation stimulated by TGFβ2 for either 2 h
(41 ± 4%) or 24 h (15 ± 3%) relative to TGFβ2-treated cells
(Figures 9A and 9C).
Figure  7.  The  TGZ  inhibition  effect  is  independent  to  PPARγ
activation. A: ARPE-19 cells were pretreated with different doses of
GW9662 (5–20 μM, 2 h) before TGZ combing with TGFβ2 treatment
for additional 48 h. Immunoblot results are from a representative
experiment  with  β-actin  as  loading  control.  B:  ARPE-19  cell
monolayers were either treated with TGFβ2 or pretreated with 10
μM  GW9662  before  TGZ  combing  with  TGFβ2  treatment  and
wounded  with  a  P-200  pipette  tip  immediately.  Wells  were
photographed at 48 h adjacent to a reference line scraped on the
bottom of the plate.
TGFβ binding to its receptor causes phosphorylation of
Figure 8. The effect of TGZ on TGFβ2-induced p38 activation. A:
ARPE-19 cells were treated with TGFβ2 alone or were pretreated
with 10 μM TGZ for 1 h and then stimulated with TGFβ2 for the
indicated time periods. Cells were harvested and subjected to western
blot analysis with phosphospecific antibodies of p38 MAPK. Equal
protein loading was confirmed by the reprobing of membranes with
total p38 MAPK antibody. B: After densitometric scans of triplicate
blots, values for p-p38 MAPK (after the induction for 6 h) were
normalized to total p38 MAPK. *p<0.05 versus untreated cells. C:
ARPE-19 cells were treated with TGFβ2 alone or were pretreated for
1 h with the SB203580 or TGZ at the indicated concentrations and
then  stimulated  with  TGFβ2  for  an  additional  6  h.  Cells  were
harvested and subjected to western blot analysis with antibodies
against phosphorylated forms of p38 MAPK and HSP27. Loading
equality was confirmed with antibodies against total p38 MAPK. D:
After densitometric scans of triplicate blots, values for p-HSP27 were
normalized  to  total  p38  MAPK.  *p<0.05  versus  untreated  cells.
#p<0.05 versus TGFβ2-treated cells.
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101Smad2 and Smad3 to form a hetero-oligomeric complex with
Smad4, which then translocates into the nucleus to regulate
transcription of target genes [25]. We thus examined if TGZ
prevented Smad2 and 3 phosphorylation that could also block
cytoplasmic Smad translocation to nucleus. Since TGZ can
suppress  TGFβ2-induced  early  (2  h)  Smad  2  and  3
Figure 9. TGZ time-dependently suppresses TGFβ2-induced Smad
phosphorylation.  A:  ARPE-19  cells  were  treated  with  4  ng/ml
TGFβ2 alone or were pretreated with 10 μM TGZ, 10 μM SB203580,
or DMSO for 1 h and then stimulated with TGFβ2 for the indicated
time periods. Cells were harvested and subjected to western blot
analysis  with  phosphospecific  antibodies  of  Smad2  and  Smad3.
Equal protein loading was confirmed by the reprobing of membranes
with total Smad2 and Smad3 antibody as loading control. B and C:
After densitometric scans of triplicate blots, values for phospho-
Smad2 and Smad3 were normalized to total Smad2 and Smad3,
respectively. *p<0.02 versus TGFβ2-treated cells.  #p<0.05 versus
TGFβ2-treated cells
phosphorylation,  the  treated  cells  were  subjected  to
subcellular fractionation and the TGZ effect was examined by
western blotting. As shown in Figure 10, as predicted, TGZ
prevented  TGFβ2-induced  Smad2  and  Smad3  nuclear
translocation (compare the nuclear fractions of TGFβ2 and
TGFβ2+TGZ).  DMSO  or  SB203580  pretreatment  had  no
effect.
DISCUSSION
Presently,  we  investigated  the  TGZ  effect  on  TGFβ2-
stimulated responses in ARPE-19 cells. Our results reveal that
TGZ pretreatment prevents TGFβ2-induced collagen type I
and fibronectin expression at both the mRNA and protein
levels. TGZ pretreatment also suppresses TGFβ2-induced cell
migration.  Moreover,  we  demonstrate  that  TGZ  inhibits
TGFβ2-induced phosphorylation of Smad2 and Smad3 and
their subsequent nuclear translocation in a time-dependent
manner. However, TGZ has no influence on TGFβ2-induced
p38  MAPK  phosphorylation.  Since  TGFβ2-induced
fibrogenesis of RPE cells is involved in both Smad and p38
MAPK signaling, we propose that the TGZ inhibitory effect
on  TGFβ2-stimulated  ARPE-19  cells  is  mediated  through
inhibition of Smad signaling.
PPARγ ligands can protect against several insults to eyes.
For example, TGZ can protect against glutamate insult in
retinal ganglion cells [26], inhibit vascular endothelial growth
factor-induced tube formation of bovine choroidal endothelial
cells, and suppress laser photocoagulation-induced choroidal
Figure  10.  TGFβ2-induced  translocation  of  Smads2/3  from  the
cytosolic to nucleus fractions is inhibited by TGZ. ARPE-19 cells
were treated with 4 ng/ml TGFβ2 alone or pretreated with 10 μM
TGZ, 10 μM SB203580 or DMSO for 1 h and then stimulated with
TGFβ2 for 2 h. Cells were harvested and aliquots containing equal
amounts of protein from cytosolic (C) and nucleus (N) fractions were
subjected to SDS–PAGE and western blot analysis. The result of one
representative assay from two similar independent experiments is
shown.
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102neovascularization lesions in rat and monkey eyes [27]. Our
results  demonstrate  that  TGZ  can  inhibit  certain  TGFβ2
stimulation  in  ARPE-19  cells;  it  may  have  an  additional
beneficial  effect  on  preventing  the  resulting  insults  of
TGFβ2-stimulated RPE cells to the retina.
Human  RPE  cells  express  both  PPARγ1  and  its
heterodimeric  partner  RXRα  [27].  Consistent  with  the
findings, we also found PPARγ protein expressed in ARPE-19
cells by immunoblotting (Figures 7A). In the present study,
we show that TGZ inhibition of TGFβ2-stimulated responses
in ARPE-19 cells is likely to be independent of the PPARγ
receptor. This suggestion is supported by the observation that
there  was  no  change  in  the  PPARγ  protein  levels  with
exposure  to  TGZ  in  the  presence  or  absence  of  TGFβ2
(Figures 7A) and pretreatment for 2 h with 1–20 μM GW9662
(a selective PPARγ antagonist) fails to reverse the inhibition
of  TGFβ2-induced  migration  and  fibronectin  production
(Figures 7).
Smad2  and  Smad3  are  major  signaling  molecules
downstream of TGFβ cell surface receptors concerned with
the activation of TGFβ gene targets. Thus, they have been
proposed as being a key therapeutic target in the treatment of
fibrosis disorders in the eye [6]. Our study demonstrates that
TGZ can inhibit TGFβ2-induced early (2 h) Smad2 and 3 and
late (24 h) Smad3 phosphorylation in ARPE-19 cells (Figure
9). During the preparation of this our manuscript, a study was
published that supports our finding that a PPARγ agonist,
GW7845, can suppress TGFβ1-mediated collagen production
of HSC via the inhibition of Smad3 phosphorylation [28].
Therefore, it is of interest to study whether TGZ and GW7845
operate through a similar molecular mechanism to inhibit
Smad3 phosphorylation.
TGFβ2 also transiently induces p38 MAPK activation
(Figure 8A) and p38 MAPK signaling has been proposed, at
least in part, in the upregulation of Smad2 and Smad3 activity
[13]. Inhibition of p38 MAPK activity also causes suppression
of TGFβ2-stimulated responses in ARPE-19 cells [12,13].
Interestingly, both presently and in a previous report [12], a
p38  MAPK  inhibitor  (SB203580)  only  partially  inhibits
TGFβ2-induced collagen type I expression (Figures 2 and 3,
TGFβ2+SB compared with TGFβ2), suggesting not all Smad
activities are controlled by p38 MAPK in ARPE-19 cells.
TGZ combining with the p38 MAPK inhibitor may provide
an inhibition similar to either treatment alone at a high dosage,
leading to decrease side-effects in vivo.
The  underlying  mechanism  of  TGZ  suppression  of
TGFβ2-induced  Smad2  and  3  phosphorylation  remains
unclear. The levels of Smad phosphorylation are induced by
binding  to  TGFβ  receptors  (activin-receptor-like  kinases;
ALKs) [25]. Decrease of Smad2 and Smad3 phosphorylation
levels by TGZ may be through interference with the TGFβ2-
ALKs  interaction  or  suppression  of  the  intrinsic  serine/
threonine  kinase  activity  of  ALKs  or  an  increase  in  an
association between ALKs and Smad7 (an inhibitory Smad)
[6]  or  induction  of  Smad7  expression  [29].  In  addition,
phosphorylation  of  Smad2  and  Smad3  is  regulated  by  a
phosphatase,  PPM1A,  that  directly  dephosphorylates  the
Smad  species  to  limit  their  activation  [30].  These  are
candidate  mediators  of  the  TGZ  effect.  The  mechanisms
involved  in  the  inhibition  of  Smad2  and  Smad3
phosphorylation by TGZ will be important to identify in future
research. In this regard, further study of the TGZ inhibitory
mechanism  may  helpful  to  explain  why  TGZ  inhibits
TGFβ2-induced C-terminal phosphorylation of Smad3 more
effectively than Smad2.
In  summary,  TGZ  pretreatment  can  suppress  certain
TGFβ2-stimulated  responses  in  ARPE-19  cells  including
collagen type I and fibronectin production, cell migration, and
the phosphorylation of Smad2 and Smad3. This finding may
contribute in part to therapeutic solutions for TGFβ-Smads2/3
pathway-mediated tissue fibrosis.
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